Tirzepatide, as a dual agonist, delivers impressive outcomes
Its cardiovascular safety in patients with cardiovascular disease or high cardiovascular risk was demonstrated in the aforementioned PIONEER-6 study.62 In the PIONEER 5 study, in patients with CKD stage 3, it was evaluated the efficacy and safety of a 14 mg dose, resulting superior to placebo in terms of reduction of HbA1c (-0.8% vs
is supported by NIDDK K23 DK131345
Post hoc comparisons revealed a significant increase in appetite scores in the control group from pre- to post-alcohol administration (B = 23.27, t(18) = 5.0, p = 0.0005), while the GLP-1RA group showed no statistically significant change (B = 7.30, t(18) = 1.57, p = 0.41), however the GLP-1 group started with a slightly, but not significantly, higher baseline